Skip to search formSkip to main contentSkip to account menu

apixaban

Known as: 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-, apixabanum, apixabán 
An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the… 
National Institutes of Health

Related topics

Related topics

10 relations
Apixaban:MCnc:Pt:PPP:Qn:ChromoApixaban:MCnc:Pt:Ser/Plas:Qnapixaban 2.5 MG Oral Tabletapixaban 5 MG Oral Tablet

Narrower (2)

BMS 562247Eliquis

Broader (3)

Factor Xa inhibitorsPyrazolesPyridones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
2019
2019
Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
Review
2019
Review
2019
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Highly Cited
2018
Highly Cited
2018
Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation　- Findings From the SAKURA AF Registry.
BACKGROUND Although direct oral anticoagulants (DOACs) are widely used in Japanese patients with atrial fibrillation (AF), large… 
2015
2015
Hemorrhagic complications of dental extractions in 181 patients undergoing double antiplatelet therapy.
Review
2014
Review
2014
Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
2012
2012
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next? - 
Highly Cited
2010
Highly Cited
2010
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome
Summary Apixaban is an oral, direct factor Xa inhibitor under development for secondary prevention in acute coronary syndrome… 
Review
2010
Review
2010
New options with dabigatran etexilate in anticoagulant therapy
Thrombosis, the localized clotting of blood, occurs in both the arterial and venous circulation, and has a major impact on health… 
Review
2008
Review
2008
Apixaban, an oral, direct inhibitor of activated Factor Xa.
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)